366 related articles for article (PubMed ID: 34048189)
1. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.
Vu TH; Nguyen HTT; Dao LK; Duong CK; Nguyen CV; Doan TT; Nguyen HTT; Hoang HH; Dinh DK; Le GV; Vu TT; Truong MC; Nguyen LT
Asian Pac J Cancer Prev; 2021 May; 22(5):1581-1590. PubMed ID: 34048189
[TBL] [Abstract][Full Text] [Related]
2. A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
Pham CP; Nguyen TTH; Do AT; Nguyen TK; Hoang TAT; Le TA; Vuong DTH; Nguyen DNT; Dang VK; Nguyen TO; Pham VL; Nguyen MH; Vo THT; Do HK; Vu HT; Nguyen TTH; Pham VT; Trinh LH; Nguyen KD; Nguyen HG; Truong CM; Pham TMC; Nguyen TBP
BMC Cancer; 2024 Feb; 24(1):176. PubMed ID: 38317094
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
Ho GF; Chai CS; Alip A; Wahid MIA; Abdullah MM; Foo YC; How SH; Zaatar A; Lam KS; Leong KW; Low JS; Yusof MM; Lee EC; Toh YY; Liam CK
BMC Cancer; 2019 Sep; 19(1):896. PubMed ID: 31500587
[TBL] [Abstract][Full Text] [Related]
4. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
[TBL] [Abstract][Full Text] [Related]
6. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
Moran T; Taus A; Arriola E; Aguado C; Dómine M; Rueda AG; Calles A; Cedrés S; Viñolas N; Isla D; Palmero R; Sereno M; Diaz V; Juan O; Marsé R; Martorell PM; Sánchez Torres JM;
Clin Lung Cancer; 2020 Sep; 21(5):428-436.e2. PubMed ID: 32461037
[TBL] [Abstract][Full Text] [Related]
7. Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam.
Pham VL; Le TA; Pham CP; Hoa Nguyen TT; Do AT; Nguyen TK; Nguyen MH; Thu Hoang TA; Hao Vuong DT; Tam Nguyen DN; Khiem Dang V; Nguyen TO; Trang Vo TH; Do HK; Vu HT; Nguyen TTH; Pham VT; Trinh LH; Dung Nguyen K; Nguyen HG; Truong CM; Chau Pham TM; Nguyen TBP
Ther Adv Med Oncol; 2024; 16():17588359241242972. PubMed ID: 38736554
[TBL] [Abstract][Full Text] [Related]
8. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S
Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973
[TBL] [Abstract][Full Text] [Related]
9. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
Hsu PC; Lee SH; Chiu LC; Lee CS; Wu CE; Kuo SC; Ju JS; Huang AC; Li SH; Ko HW; Yang CT; Wang CC
Target Oncol; 2023 Mar; 18(2):195-207. PubMed ID: 36805452
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.
Pang LL; Gan JD; Tan JR; Huang YH; Liao J; Liang WT; Deng PB; Fang WF
Cancer; 2022 Nov; 128(21):3804-3814. PubMed ID: 36069292
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
Popat S; Hsia TC; Hung JY; Jung HA; Shih JY; Park CK; Lee SH; Okamoto T; Ahn HK; Lee YC; Sato Y; Lee SS; Mascaux C; Daoud H; Märten A; Miura S
Oncologist; 2022 Apr; 27(4):255-265. PubMed ID: 35274704
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
Minegishi Y; Yamaguchi O; Sugawara S; Kuyama S; Watanabe S; Usui K; Mori M; Hataji O; Nukiwa T; Morita S; Kobayashi K; Gemma A
BMC Cancer; 2021 Mar; 21(1):208. PubMed ID: 33648453
[TBL] [Abstract][Full Text] [Related]
13. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
Kim Y; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
Cancer Res Treat; 2019 Apr; 51(2):502-509. PubMed ID: 29898592
[TBL] [Abstract][Full Text] [Related]
15. Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.
Ezeife DA; Melosky B; Tudor R; Lin S; Lau A; Panzarella T; Leighl NB
Curr Oncol; 2018 Oct; 25(5):e385-e390. PubMed ID: 30464688
[TBL] [Abstract][Full Text] [Related]
16. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Paz-Ares L; Tan EH; O'Byrne K; Zhang L; Hirsh V; Boyer M; Yang JC; Mok T; Lee KH; Lu S; Shi Y; Lee DH; Laskin J; Kim DW; Laurie SA; Kölbeck K; Fan J; Dodd N; Märten A; Park K
Ann Oncol; 2017 Feb; 28(2):270-277. PubMed ID: 28426106
[TBL] [Abstract][Full Text] [Related]
17. Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
Yamaguchi O; Kaira K; Mouri A; Shiono A; Hashimoto K; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
Cancer Chemother Pharmacol; 2019 May; 83(5):817-825. PubMed ID: 30758646
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
Imai H; Kaira K; Suzuki K; Anzai M; Tsuda T; Ishizuka T; Kuwako T; Naruse I; Nemoto K; Uchino J; Morozumi N; Ishihara S; Minato K; Hisada T
Lung Cancer; 2018 Dec; 126():41-47. PubMed ID: 30527191
[TBL] [Abstract][Full Text] [Related]
19. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
van Veggel BAMH; van der Wekken AJ; Paats MS; Hendriks LEL; Hashemi SMS; Daletzakis A; van den Broek D; Bosch LJW; Monkhorst K; Smit EF; de Langen AJ
Cancer; 2024 Mar; 130(5):683-691. PubMed ID: 37905752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]